Press Releases BiomX Inc.

Equities

PHGE

US09090D1037

Market Closed - Nyse Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
0.3701 ^USD	-11.46%		+5.74%	+32.18%

May. 21	Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
May. 20	BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers	Jun. 03	AQ
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	May. 30	GL
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	May. 30	AQ
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024	May. 30	GL
BiomX : Introduction	May. 21	PU
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates	May. 21	GL
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024	May. 15	GL
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases	Apr. 24	AQ
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)	Apr. 23	AQ
BiomX Announces the Appointment of Susan Blum to its Board of Directors	Apr. 18	AQ
BiomX : Introduction	Apr. 04	PU
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure	Apr. 04	AQ
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Apr. 03	AQ
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024	Mar. 27	AQ
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing	Mar. 18	AQ
BiomX : Material Agreement - Form 8-K	Mar. 06	PU
BiomX : Introduction	Mar. 06	PU
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing	Mar. 06	AQ
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis	Jan. 04	AQ
BiomX : CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 CONTENTS - Form 8-K	Dec. 07	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BiomX Inc.

Equities

PHGE

US09090D1037

Press Releases

Filters